Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2016, Article ID 2909576, 9 pages
http://dx.doi.org/10.1155/2016/2909576
Research Article

The Initial Months of Antiretroviral Therapy and Its Influence on AGEs, HMGB1, and sRAGE Levels in Asymptomatic HIV-Infected Individuals

1Department of Tropical Diseases, Botucatu Medical School (FMB), Universidade Estadual Paulista (UNESP), Botucatu, SP, Brazil
2Department of Pathology, FMB/UNESP, Botucatu, SP, Brazil
3Hemocenter, FMB/UNESP, Botucatu, SP, Brazil
4Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy

Received 8 July 2016; Revised 4 October 2016; Accepted 26 October 2016

Academic Editor: Gabriella D’Ettorre

Copyright © 2016 Karen Ingrid Tasca et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. UNAIDS.org. Joint United Nations Programme on HIV/AIDS, Global AIDS Response Progress Reporting, 2015, http://www.unaids.org/en/dataanalysis/knowyourresponse/globalaidsprogressreporting/.
  2. C. S. Rodrigues, M. D. Guimarães, F. A. Acurcio, and C. C. Comini, “Interrupção do acompanhamento clínico ambulatorial de pacientes infectados pelo HIV,” Revista de Saúde Publica, vol. 37, no. 2, pp. 183–190, 2003. View at Google Scholar
  3. A. J. Aberg, “Aging, inflammation, and HIV,” Topics in Antiviral Medicine, vol. 20, no. 3, pp. 101–105, 2012. View at Google Scholar
  4. Ministério da Saúde, Departamento de DST, Aids e Hepatites Virais, Boletim Epidemiologia Dst Aids, 2014.
  5. G. Guaraldi, G. Orlando, S. Zona et al., “Premature age-related comorbidities among HIV-infected persons compared with the general population,” Clinical Infectious Diseases, vol. 53, no. 11, pp. 1120–1126, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. K. V. Ramana, “Effect of highly active antiretroviral therapy (HAART) on human immunodeficiency virus disease pathogenesis and progression,” American Journal of Public Health Reserch, vol. 2, no. 3, pp. 68–74, 2014. View at Publisher · View at Google Scholar
  7. S. G. Deeks, “HIV infection, inflammation, immuno-senescence, and aging,” Annual Review of Medicine, vol. 62, pp. 141–155, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Venkataramana, “A study of biological markers in HIV disease progression and management in the highly active antiretroviral therapy (HAART) era,” American Journal of Bioscience and Bioenginnering, vol. 1, no. 2, pp. 24–37, 2013. View at Google Scholar
  9. T. Hulgan, J. Morrow, R. T. D'Aquila et al., “Oxidant stress is increased during treatment of human immunodeficiency virus infection,” Clinical Infectious Diseases, vol. 37, no. 12, pp. 1711–1717, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. B. I. Hudson, A. M. Holfmann, L. Bucciarelli et al., “Glycation and diabetes: the RAGE connection,” Current Science, vol. 83, no. 12, pp. 1515–1521, 2002. View at Google Scholar
  11. B. K. Kilhovd, T. J. Berg, K. I. Birkeland, P. Thorsby, and K. F. Hanssen, “Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease,” Diabetes Care, vol. 22, no. 9, pp. 1543–1548, 1999. View at Publisher · View at Google Scholar · View at Scopus
  12. B. Knysz, B. Szetela, and A. Gładysz, “Pathogenesis of HIV-1 infection—chosen aspects,” HIV & AIDS Review, vol. 6, no. 1, pp. 7–11, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Pietschmann, D. Mechtcheriakova, A. Meshcheryakova, U. Föger-Samwald, and I. Ellinger, “Immunology of osteoporosis: a mini-review,” Gerontology, vol. 62, no. 2, pp. 128–137, 2016. View at Publisher · View at Google Scholar
  14. M. Kaneko, L. Bucciarelli, Y. C. Hwang et al., “Aldose reductase and AGE-RAGE pathways: key players in myocardial ischemic injury,” Annals of the New York Academy of Sciences, vol. 1043, pp. 702–709, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. A. G. Huebschmann, J. G. Regensteiner, H. Vlassara, and J. E. B. Reusch, “Diabetes and advanced glycoxidation end products,” Diabetes Care, vol. 29, no. 6, pp. 1420–1432, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. V. Srikanth, A. Maczurek, T. Phan et al., “Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease,” Neurobiology of Aging, vol. 32, no. 5, pp. 763–777, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. G. P. Sims, D. C. Rowe, S. T. Rietdijk, R. Herbst, and A. J. Coyle, “HMGB1 and RAGE in inflammation and cancer,” Annual Review of Immunology, vol. 28, pp. 367–388, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Kierdorf and G. Fritz, “RAGE regulation and signaling in inflammation and beyond,” Journal of Leukocyte Biology, vol. 94, no. 1, pp. 55–68, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Z. Kalea, A. M. Schmidt, and B. I. Hudson, “RAGE: a novel biological and genetic marker for vascular disease,” Clinical Science, vol. 116, no. 8, pp. 621–637, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. A. M. Schmidt, S. D. Yan, S. F. Yan, and D. M. Stern, “The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses,” Journal of Clinical Investigation, vol. 108, no. 7, pp. 949–955, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. S. J. Jeong, C. O. Kim, Y. G. Song et al., “Low plasma levels of the soluble receptor for advanced glycation end products in HIV-infected patients with subclinical carotid atherosclerosis receiving combined antiretroviral therapy,” Atherosclerosis, vol. 219, no. 2, pp. 778–783, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Santilli, L. Bucciarelli, D. Noto et al., “Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins,” Free Radical Biology & Medicine, vol. 43, no. 9, pp. 1255–1262, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Geroldi, C. Falcone, E. Emanuele et al., “Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension,” Journal of Hypertension, vol. 23, no. 9, pp. 1725–1729, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. J. O. Thomas, “HMG 1 and 2: architectural DNA-binding proteins,” Biochemical Society Transactions, vol. 29, no. 4, pp. 395–401, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Scaffidi, T. Misteli, and M. E. Bianchi, “Release of chromatin protein HMGB1 by necrotic cells triggers inflammation,” Nature, vol. 418, pp. 191–195, 2002. View at Publisher · View at Google Scholar
  26. J. Tian, A. M. Avalos, S.-Y. Mao et al., “Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE,” Nature Immunology, vol. 8, no. 5, pp. 487–496, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. J. H. Youn, Y. J. Oh, E. S. Kim, J. E. Choi, and J.-S. Shin, “High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-α production in human monocytes,” The Journal of Immunology, vol. 180, no. 7, pp. 5067–5074, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. V. Urbonaviciute, B. G. Fürnrohr, S. Meister et al., “Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE,” Journal of Experimental Medicine, vol. 205, no. 13, pp. 3007–3018, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. M.-L. Gougeon, M.-T. Melki, and H. Saïdi, “HMGB1, an alarmin promoting HIV dissemination and latency in dendritic cells,” Cell Death & Differentiation, vol. 19, no. 1, pp. 96–106, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. U. Andersson and H. E. Harris, “The role of HMGB1 in the pathogenesis of rheumatic disease,” Biochimica et Biophysica Acta—Gene Regulatory Mechanisms, vol. 1799, no. 1-2, pp. 141–148, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Yasuda, T. Ueda, Y. Takeyama et al., “Significant increase of serum high-mobility group box chromosomal protein 1 levels in patients with severe acute pancreatitis,” Pancreas, vol. 33, no. 4, pp. 359–363, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Zhang, J. Zhong, P. Yang, F. Gong, and C.-Y. Wang, “HMGB1, an innate alarmin, in the pathogenesis of type 1 diabetes,” International Journal of Clinical and Experimental Pathology, vol. 3, no. 1, pp. 24–38, 2010. View at Google Scholar · View at Scopus
  33. D. V. Havlir, I. C. Marschner, M. S. Hirsch et al., “Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy,” The New England Journal of Medicine, vol. 339, no. 18, pp. 1261–1268, 1998. View at Publisher · View at Google Scholar · View at Scopus
  34. A. E. C. G. Fukumoto, C. C. Oliveira, K. I. Tasca, and L. D. R. D. Souza, “Evolution of patients with AIDS after cART: clinical and laboratory evolution of patients with AIDS after 48 weeks of antiretroviral treatment,” Revista do Instituto de Medicina Tropical de Sao Paulo, vol. 55, no. 4, pp. 267–273, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. L. F. D. S. Pinto Neto, M. B. das Neves, R. Ribeiro-Rodrigues, K. Page, and A. E. Miranda, “Dyslipidemia and fasting glucose impairment among HIV patients three years after the first antiretroviral regimen in a Brazilian AIDS outpatient clinic,” Brazilian Journal of Infectious Diseases, vol. 17, no. 4, pp. 438–443, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. S. J. Souza, L. A. Luzia, S. Santos, and P. H. C. Rondó, “Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review,” Revista da Associação Médica Brasileira, vol. 59, no. 2, pp. 186–198, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. J. M. Brenchley, D. A. Price, T. W. Schacker et al., “Microbial translocation is a cause of systemic immune activation in chronic HIV infection,” Nature Medicine, vol. 12, no. 12, pp. 1365–1371, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. D. C. Hsu, I. Sereti, and J. Ananworanich, “Serious Non-AIDS events: immunopathogenesis and interventional strategies,” AIDS Research and Therapy, vol. 10, no. 1, article 29, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. P. W. Hunt, “HIV and inflammation: mechanisms and consequences,” Current HIV/AIDS Reports, vol. 9, no. 2, pp. 139–147, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. J. L. Fahey, “Plasma immune activation markers, and clinically relevant surrogate markers in human immunodeficiency virus infection,” Cytokines, vol. 5, no. 5, pp. 597–603, 1998. View at Google Scholar
  41. S. Hattab, A. Guihot, M. Guiguet et al., “Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: An Observational Study,” BMC Infectious Diseases, vol. 14, no. 1, article 122, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Masiá, E. Bernal, S. Padilla et al., “The role of C-reactive protein as a marker for cardiovascular risk associated with antiretroviral therapy in HIV-infected patients,” Atherosclerosis, vol. 195, no. 1, pp. 167–171, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. M. M. M. Guimarães, D. B. Greco, S. M. D. Figueiredo, R. B. Fóscolo, A. R. D. Oliveira Jr., and L. J. D. C. Machado, “High-sensitivity C-reactive protein levels in HIV-infected patients treated or not with antiretroviral drugs and their correlation with factors related to cardiovascular risk and HIV infection,” Atherosclerosis, vol. 201, no. 2, pp. 434–439, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Bestawros, T. Chidumayo, M. Blevins et al., “Increased systemic inflammation is associated with cardiac and vascular dysfunction over the first 12 weeks of antiretroviral therapy among undernourished, HIV-infected adults in Southern Africa,” Journal of AIDS and Clinical Research, vol. 6, no. 3, p. 431, 2015. View at Google Scholar
  45. B. Lindegaard, T. Hansen, T. Hvid et al., “The effect of strength and endurance training on insulin sensitivity and fat distribution in human immunodeficiency virus-infected patients with lipodystrophy,” The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 10, pp. 3860–3869, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. L. A. Willig and E. T. Overton, “Metabolic complications and glucose metabolism in HIV infection: a review of the evidence,” Current HIV/AIDS Report, vol. 13, pp. 289–296, 2016. View at Google Scholar
  47. R. D. Semba, E. J. Nicklett, and L. Ferrucci, “Does accumulation of advanced glycation end products contribute to the aging phenotype?” Journals of Gerontology—Series A, vol. 65, no. 9, pp. 963–975, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. A. I. Serban, L. Stanca, O. I. Geicu, and A. Dinischiotu, “Ages-induced IL-6 synthesis precedes RAGE up-regulation in HEK 293 cells: an alternative inflammatory mechanism?” International Journal of Molecular Sciences, vol. 16, no. 9, pp. 20100–20117, 2015. View at Publisher · View at Google Scholar · View at Scopus
  49. B. I. Hudson, C. Dong, H. Gardener et al., “Serum levels of soluble receptor for advanced glycation end-products and metabolic syndrome: the Northern Manhattan Study,” Metabolism: Clinical and Experimental, vol. 63, no. 9, pp. 1125–1130, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Wang, O. Bloom, M. Zhang et al., “HMG-1 as a late mediator of endotoxin lethality in mice,” Science, vol. 285, no. 5425, pp. 248–251, 1999. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Thierry, J. Gozlan, A. Jaulmes et al., “High-mobility group box 1 protein induces HIV-1 expression from persistently infected cells,” AIDS, vol. 21, no. 3, pp. 283–292, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. P. Nowak, B. Barqasho, and A. Sönnerborg, “Elevated plasma levels of high mobility group box protein 1 in patients with HIV-1 infection,” AIDS, vol. 21, no. 7, pp. 869–871, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Trøseid, A. Sönnerborg, and P. Nowak, “High mobility group box protein-1 in HIV-1 infection: connecting microbial translocation, cell death and immune activation,” Current HIV Research, vol. 9, no. 1, pp. 6–10, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Uribarri, M. D. del Castillo, M. P. de la Maza et al., “Dietary advanced glycation end products and their role in health and disease,” Advances in Nutrition, vol. 6, no. 4, pp. 461–473, 2015. View at Publisher · View at Google Scholar · View at Scopus